Benchmarking the impact of "vaccines"
Over the last 40 years or so I have accumulated experience in the investment industry, culminating in being part of a global team advising large corporate, state and local pension funds on which investment managers to select for which fixed income mandates worth, in total, more than a trillion dollars. I have been an investment manager of life, general and re-insurance funds, pension funds and central bank reserves, an interbank broker of cash, bonds, FRA#s and Interest Rate Swaps, a licensed stock exchange operator and managed my own personal assets in global markets.
For a decade or so, I also ran a team that monitored the performance of in-house and “out-house” investment funds for middle eastern investment authorities, asian foreign exchange funds, government reserve funds and so on.
It is the last aspect that is useful in today’s environment of assessing the utility and risk/benefit analysis of covid19 injections.
Using two investment performance measures - 1. benchmark relative performance measurement and attribution analysis and 2. Benchmark Relative VaR analysis - the risks and benefits of “vaccines” can be assessed.
Benchmark relative performance measurement and attribution is based on excess positive or negative returns, relative to a benchmark. Instead of relative investment returns per sector and relative weights per sector, deaths per 100,000 population per cause of death can be used. Benchmark can be pre-CoVID19 (e.g 2010-2019) or can be unvaccinated v vaccinated over the course of the pandemic. Monthly numbers are required.
Benchmark relative VaR states the risk in the bell curve of probabilities that lie to the left of the 5% point of the entire distribution of outcomes. This can be converted from return outcomes to mortality outcomes.
More to come. Takes a lot of time and the gathering of a lot of data, but the large investment management houses, banks, consulting firms and actuaries each have the in-house expertise and tools to do this work. Me? Not so much!